TRAX (First Tracks Biotherapeutics) Total Debt per Share: $0.46 (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $44.64
! 2 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Total Debt per Share?

First Tracks Biotherapeutics TRAX +1.36% 12 Total Debt per Share is $0.46 as of Dec. 2024. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

$0.46 (As of Dec. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. First Tracks Biotherapeutics's Total Debt Per Share for the quarter that ended in Dec. 2024 was $0.46.

First Tracks Biotherapeutics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Total Debt per Share Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Total Debt per Share
0.51 0.46

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Total Debt per Share 0.51 0.46
TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Total Debt per Share Calculation

First Tracks Biotherapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(14.11+1.93)/34.75
=0.46

First Tracks Biotherapeutics's Total Debt Per Share for the quarter that ended in Dec. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(14.11+1.93)/34.75
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.46 mean?
First Tracks Biotherapeutics (TRAX) has a Total Debt per Share of $0.46 as of Dec. 2024. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Total Debt per Share too high?
First Tracks Biotherapeutics' current Total Debt per Share is $0.46. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Total Debt per Share compare to AVLN and IMTX?
First Tracks Biotherapeutics' Total Debt per Share of $0.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Total Debt per Share is $0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current Total Debt per Share of $0.46. The current Total Debt per Share is $0.46. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current Total Debt per Share is $0.46 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.64
Price